0001209191-21-045948.txt : 20210707
0001209191-21-045948.hdr.sgml : 20210707
20210707203859
ACCESSION NUMBER: 0001209191-21-045948
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210706
FILED AS OF DATE: 20210707
DATE AS OF CHANGE: 20210707
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Detke Michael J.
CENTRAL INDEX KEY: 0001770786
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 211078710
MAIL ADDRESS:
STREET 1: C/O CORTEXYME, INC.
STREET 2: 269 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cortexyme, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-06
0
0001662774
Cortexyme, Inc.
CRTX
0001770786
Detke Michael J.
C/O CORTEXYME, INC.
269 EAST GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
2021-07-06
4
M
0
12600
2.23
A
40861
D
Common Stock
2021-07-06
4
S
0
32313
53.43
D
8548
D
Common Stock
2021-07-06
4
S
0
8260
53.91
D
288
D
Common Stock
2021-07-06
4
S
0
288
55.01
D
0
D
Common Stock
2021-07-07
4
M
0
17400
2.23
A
17400
D
Common Stock
2021-07-07
4
S
0
3934
53.24
D
13466
D
Common Stock
2021-07-07
4
S
0
1648
54.37
D
11818
D
Common Stock
2021-07-07
4
S
0
4353
55.38
D
7465
D
Common Stock
2021-07-07
4
S
0
6942
56.27
D
523
D
Common Stock
2021-07-07
4
S
0
523
56.99
D
0
D
Stock Option (right to buy)
2.23
2021-07-06
4
M
0
12600
0.00
D
2028-11-27
Common Stock
12600
119752
D
Stock Option (right to buy)
2.23
2021-07-07
4
M
0
17400
0.00
D
2028-11-27
Common Stock
17400
102352
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.69 to $53.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.71 to $54.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.745 to $53.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.75 to $54.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.79 to $55.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.81 to $57.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022.
/s/ Caryn Gordon McDowell, Attorney-in-Fact for Michael J. Detke, M.D.
2021-07-07